Cost-benefit studies of vaccinations in Finland.
The benefits of vaccination are, in general, recognized. For some diseases these benefits are obvious. When starting or evaluating new vaccination programmes, a more critical approach is needed. Before starting vaccination against measles and rubella in Finland a cost-benefit study was performed. According to those studies the net benefits of each vaccination would be ca. 100 million Finnish marks in 25-30 years. Those benefits not measurable in money value of human life, decrease of suffering, etc., were not included. For the purpose of formulating the national influenza vaccination policy a similar study was performed on influenza. The method used before seemed to be less suitable, however, with certain assumptions the vaccinations against influenza proved to be profitable.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D005387:Finland; D006801:Humans; D007223:Infant; D007251:Influenza, Human / Q000517:prevention & control; D008457:Measles / Q000517:prevention & control; D008458:Measles Vaccine / Q000627:therapeutic use; D009975:Orthomyxoviridae / Q000276:immunology; D012409:Rubella / Q000517:prevention & control; D012411:Rubella Vaccine / Q000627:therapeutic use; D014611:Vaccination / Q000191:economics*; D014765:Viral Vaccines / Q000627:therapeutic use
D008458:Measles Vaccine; D012411:Rubella Vaccine; D014765:Viral Vaccines